Sanofi (SANP.XC)
Cboe UK - Cboe UK Real-time price. Currency in EUR
Add to watchlist
At close: 04:23PM BST
| Previous close | 90.07 |
| Open | 90.28 |
| Bid | 88.81 x 0 |
| Ask | 89.43 x 0 |
| Day's range | 89.13 - 90.29 |
| 52-week range | 80.89 - 104.24 |
| Volume | |
| Avg. volume | 292 |
| Market cap | 111.596B |
| Beta (5Y monthly) | 0.44 |
| PE ratio (TTM) | 24.69 |
| EPS (TTM) | 3.61 |
| Earnings date | 25 July 2024 |
| Forward dividend & yield | 3.76 (4.17%) |
| Ex-dividend date | 13 May 2024 |
| 1y target est | N/A |
ZacksThe Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers are included in this Analyst Blog.
ZacksBiotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
Novavax, Inc (NVAX) and Fulcrum Therapeutics, Inc (FULC) are in the spotlight following license agreements with pharma giant Sanofi.
FX EmpireNovavax Soars on Sanofi Deal: A Smart Buy or Post-Hype Correction?
The past five days have been a rollercoaster for Novavax investors, as the share price of the company skyrocketed by over 200% following the announcement of a major deal with French pharmaceutical giant Sanofi.
© 2024 Yahoo. All rights reserved.